eFFECTOR Therapeutics, Inc. Profile Avatar - Palmy Investing

eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of…

Biotechnology
US, Solana Beach [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of EFTR's Analysis
CIK: 1828522 CUSIP: 28202V108 ISIN: US28202V2079 LEI: - UEI: -
Secondary Listings
EFTR has no secondary listings inside our databases.